User Fee Deadline Concerns Emerge As US FDA Buyout Offer Sweetened With Paid Leave

 
• By Sarah Karlin-Smith
  
snail with a stopwatch on its back on yellow background
Project manager eligibility for a new buyout offer at the FDA could lead to slower drug review times. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA

More from Pathways & Standards